- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02422238
Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease (NAFLD-cohort)
Disease Mechanisms and Markers for Non-alcoholic Steatohepatitis in a Population With Non-alcoholic Fatty Liver Disease: a Prospective Cohort Study With Biobank
Study Overview
Status
Conditions
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) is with 20-30% the most prevalent liver disorder in Western society. Most patients with NAFLD have no or few, mainly aspecific symptoms; and generally there is a silent progression of simple steatosis to NASH and in the end liver-related morbidity and mortality.
Further insight in factors contributing to the initiation of NASH in patients with simple steatosis and early diagnosis are essential for identifying future therapeutic options and to limit the risk of complicated NASH (i.e. fibrosis, and cirrhosis with portal hypertension) HCC, liver-related mortality and extrahepatic morbidity.
This cohort study, with both a cross-sectional and a longitudinal part, will include obese subjects (BMI ≥ 30 kg/m2, age 18-65) with proven NAFLD based on liver biopsy and/or MRI.
All participants will be asked to complete several questionnaires (i.e. demographics, clinical data, SF-36, GAD-7 and PHQ-9, FFQ, SQUASH, and Baecke), and to undergo anthropometric measurements. Furthermore, blood, urine, faeces and exhaled air will be collected and a fibroscan and DEXA-scan will be performed. Additionally, participants will be asked to participate in a multi-sugar test for intestinal permeability.
The majority of eligible subjects will undergo/have undergone a MRI or liver biopsy for clinical reasons. It is to be expected that about 33% of subjects will be asked to undergo a MRI for study purpose only.
After 5 and 10 years, participants will be invited to undergo in the same study procedures, data and sample collection to study the factors responsible for the development of NASH in the group with simple steatosis at baseline, and the development of (extra)hepatic complications in the group with NASH at baseline.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Koek, MD, PhD
- Phone Number: 0031-43-3875021
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands
- Recruiting
- Maastricht University Medical Center
-
Contact:
- Koek, MD, PhD
- Phone Number: 0031-43-3875021
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- NAFLD diagnosis based on evidence of hepatic steatosis, either by imaging (using MRI) or by histology.
- BMI ≥ 30 kg/m2
- Between 18 - 65 years of age
Exclusion Criteria:
- Incompetent to understand and/or sign the informed consent.
- Causes for secondary hepatic fat accumulation such as significant alcohol consumption, medications, Wilson's disease, viral infections, starvation or parenteral nutrition, among others, and conditions associated with microvesicular steatosis
- Ethanol consumption exceeding more than 14 standard beverages per week for males and more than 7 standard beverages per week for female.
- Not able or willing to undergo MRI (for example claustrophobia, ICD, pacemaker).
- Not willing to be informed about unexpected findings by MRI
- Unwilling to collect bio samples.
- Pregnancy and breastfeeding.
- Indication or planned for bariatric surgery within one year after inclusion or a history of bariatric surgery.
- Diagnosis of liver cirrhosis and/or hepatocellular carcinoma.
- Current diagnosis of extrahepatic malignancy(s) or prior diagnosis within last 5 years.
- Individuals about to undergo or recovering from a surgical or otherwise medical procedure that will interfere with data collection and analyses planned within the current cohort, will initially be excluded from participation, but are offered the opportunity to participate at a later moment in time
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Development of NASH
Time Frame: 10 years
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Prevalence of hepatic complications of NAFLD
Time Frame: 10 years
|
10 years
|
Prevalence of extrahepatic complications of NAFLD
Time Frame: 10 years
|
10 years
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- METC142074
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Fatty Liver Disease
-
Columbia UniversityThorne Research Inc.WithdrawnNASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver Disease
-
Merck Sharp & Dohme LLCRecruitingNon-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Fatty Liver, NonalcoholicCanada, United States, Puerto Rico, Israel, Japan, Korea, Republic of, Taiwan, Spain, Chile, France, Italy, Hungary, Switzerland, Belgium, China, Singapore, Czechia, Portugal, Austria, United Kingdom, Thailand, Hong Kong, Turkey
-
University of AarhusCompletedNASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver DiseaseDenmark
-
Columbia UniversityPfizerWithdrawnNASH (Nonalcoholic Steatohepatitis) | NAFLD (Nonalcoholic Fatty Liver Disease)
-
AdventHealth Translational Research InstituteCompletedNASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver DiseaseUnited States
-
AstraZenecaCompletedNon-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | NASH | Fatty Liver, NonalcoholicUnited States
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Assistance Publique - Hôpitaux de ParisCompletedNonalcoholic Fatty Liver Disease (NAFLD)France
-
Massachusetts General HospitalCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States